The price-to-earnings ratio for Novo Nordisk ADR (NYSE: NVO) is 23.68x, which is above its average ratio. Moreover, the 36-month beta value for NVO is 0.67. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
The public float for NVO is 3.37B and currently, short sellers hold a 1.00% of that float. On June 16, 2025, NVO’s average trading volume was 9.98M shares.
NVO) stock’s latest price update
Novo Nordisk ADR (NYSE: NVO)’s stock price has plunge by -1.51relation to previous closing price of 81.05. Nevertheless, the company has seen a 6.97% surge in its stock price over the last five trading sessions. barrons.com reported 2025-06-13 that The Danish drug maker is being more forceful since its CEO departed last month.
NVO’s Market Performance
Novo Nordisk ADR (NVO) has experienced a 6.97% rise in stock performance for the past week, with a 23.94% rise in the past month, and a 3.47% rise in the past quarter. The volatility ratio for the week is 3.08%, and the volatility levels for the past 30 days are at 2.36% for NVO. The simple moving average for the last 20 days is 10.82% for NVO stock, with a simple moving average of -13.86% for the last 200 days.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with BMO Capital Markets repeating the rating for NVO by listing it as a “Market Perform.” The predicted price for NVO in the upcoming period, according to BMO Capital Markets is $64 based on the research report published on April 17, 2025 of the current year 2025.
NVO Trading at 18.48% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.12% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVO starting from Novo Nordisk A/S, who proposed sale 921,897 shares at the price of $2.14 back on May 30 ’25. After this action, Novo Nordisk A/S now owns shares of Novo Nordisk ADR, valued at $1,972,859 using the latest closing price.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.45 for the present operating margin
- 0.84 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.35. The total capital return value is set at 0.53. Equity return is now at value 87.53, with 26.37 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at 1.11. The debt to equity ratio resting at 0.86. The interest coverage ratio of the stock is 17.84.
Currently, EBITDA for the company is 137.38 billion with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 7.88. The receivables turnover for the company is 3.51for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To wrap up, the performance of Novo Nordisk ADR (NVO) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
